Generic

Amneal Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Friday, March 1, 2024

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December 31, 2023.
  • Net revenue in the fourth quarter of 2023 was $617 million, an increase of 1% compared to $610 million in the fourth quarter of 2022.
  • Adjusted EBITDA(1) in the fourth quarter of 2023 was $142 million, a decrease of 8% compared to the fourth quarter of 2022, primarily due to investments in research and development and commercial to drive future growth.
  • Adjusted diluted EPS(1) in the fourth quarter of 2023 was $0.14, a decrease of 39% from $0.23 in the fourth quarter of 2022.

Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open

Retrieved on: 
Friday, February 9, 2024

The trial met its primary and key secondary endpoints, making ensitrelvir (Generic name: ensitrelvir fumaric acid, Code No.

Key Points: 
  • The trial met its primary and key secondary endpoints, making ensitrelvir (Generic name: ensitrelvir fumaric acid, Code No.
  • “We’re pleased to present the data from our Phase 3 study conducted in Asia in this peer-reviewed article.
  • These results demonstrate accelerated resolution in a range of symptoms, reinforcing the potential of ensitrelvir across multiple patient profiles.
  • Among the most common treatment-related adverse events were temporary decreases in high-density lipoprotein and increased blood triglycerides, as observed in previous studies.

United States $36.8 Bn Active Pharmaceutical Ingredient Markets, Competition, Forecast and Opportunities, 2018-2022 and 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 12, 2023

Rising Prevalence of Cancer: The increasing prevalence of cancer is leading to a higher demand for APIs, particularly for targeted therapies and advanced treatment modalities.

Key Points: 
  • Rising Prevalence of Cancer: The increasing prevalence of cancer is leading to a higher demand for APIs, particularly for targeted therapies and advanced treatment modalities.
  • Advancements in Oncology Drug Research: The sophistication of oncology drug research is driving the development of high-efficacy drugs, increasing the need for specialized APIs.
  • The North-East region of the United States is expected to dominate the API market, primarily due to the presence of leading pharmaceutical companies, research infrastructure, and favorable government policies.
  • Company Profiles: Detailed analysis of the major companies present in the United States Active Pharmaceutical Ingredient Market.

KNIME Releases Improved UI, Enhanced AI Assistant, Modernized Scripting Experience with AI, and More

Retrieved on: 
Thursday, December 7, 2023

KNIME , the software company focused on making working with data intuitive, today announced KNIME Analytics Platform 5.2, the latest release of its open-source platform.

Key Points: 
  • KNIME , the software company focused on making working with data intuitive, today announced KNIME Analytics Platform 5.2, the latest release of its open-source platform.
  • KNIME Analytics Platform is free and open in nature, making data science and analytics accessible to virtually everyone via its low-code/no-code interface.
  • To enable all users to do more with their data, KNIME Analytics Platform 5.2 features enhancements to the KNIME AI Assistant as well as a significantly improved user interface based on community feedback, amongst others.
  • This release introduces a new editor with a totally modernized UI for the Python scripting node and a new Generic ECharts View node, giving users an enhanced scripting experience.

Global Merchant API Market to Reach $90.97 Billion by 2023, Fueled by Rising Diabetes Incidence and Growing Outsourcing Trend - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 9, 2023

The global merchant API market is on track to achieve a market value of US$90.97 billion by 2023, with a notable Compound Annual Growth Rate (CAGR) of 6.97% over the forecast period.

Key Points: 
  • The global merchant API market is on track to achieve a market value of US$90.97 billion by 2023, with a notable Compound Annual Growth Rate (CAGR) of 6.97% over the forecast period.
  • Pharmaceutical companies are increasingly outsourcing manufacturing to focus on core competencies like research and development (R&D) and marketing, contributing to the growth of the merchant API market.
  • The global merchant API market is segmented as follows:
    Molecular Type: This segment is divided into Small Molecules and Large Molecules.
  • Small molecules currently hold the largest market share due to the growing demand for small-molecule drugs and the outsourcing trend.

ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance

Retrieved on: 
Wednesday, November 8, 2023

-- Generics, Established Brands and Other reported net sales of $102.1 million, representing year-over-year growth of 43.4% --

Key Points: 
  • Nikhil Lalwani, President and CEO of ANI stated, “Strong execution has resulted in another record quarter for revenue and adjusted non-GAAP EBITDA, positioning us to raise full year 2023 guidance for the third consecutive quarter.
  • Third Quarter 2023 Financial Highlights:
    Net revenues were $131.8 million compared to $83.8 million in Q3 2022.
  • Since the launch of Cortrophin Gel, the overall ACTH category has experienced six consecutive quarters of year-over-year growth from second quarter 2022 to third quarter 2023.
  • Sales of generic pharmaceuticals products, established brands and other grew 43.4% year-over-year in the third quarter of 2023.

Westinghouse to Design Fuel for Rolls-Royce’s Small Modular Reactor

Retrieved on: 
Wednesday, October 11, 2023

Westinghouse Electric Company announced today an agreement with Rolls-Royce SMR Ltd to support the development and the design of the nuclear fuel for Rolls-Royce’s Small Modular Reactor program.

Key Points: 
  • Westinghouse Electric Company announced today an agreement with Rolls-Royce SMR Ltd to support the development and the design of the nuclear fuel for Rolls-Royce’s Small Modular Reactor program.
  • View the full release here: https://www.businesswire.com/news/home/20231011445475/en/
    The Westinghouse Springfields site has manufactured world-class nuclear fuel and related products and services for nearly 75 years.
  • “Westinghouse has a strong heritage and unrivalled experience in nuclear fuel design and manufacturing.
  • Westinghouse is proud to bring its generations of experience designing and manufacturing fuel in the U.K.,” said Tarik Choho, Westinghouse President of Nuclear Fuel.

IDWeek 2023: Shionogi and Qpex Biopharma, Inc. Continue Longstanding Commitment to Addressing Unmet Needs in Infectious Disease

Retrieved on: 
Thursday, September 7, 2023

: S-217622, hereafter “ensitrelvir”), and Fetroja® (cefiderocol), an antibiotic marketed under the brand name Fetcroja® in Europe.

Key Points: 
  • : S-217622, hereafter “ensitrelvir”), and Fetroja® (cefiderocol), an antibiotic marketed under the brand name Fetcroja® in Europe.
  • Shionogi recently extended its infectious disease innovation platform with the acquisition of Qpex Biopharma Inc. (Qpex) in July.
  • The acquisition brings a novel investigational ß-lactamase inhibitor to Shionogi, expanding the company’s pipeline of critically needed antimicrobials, and further augmenting its R&D capabilities and expertise.
  • During IDWeek, Shionogi will host a Learning Lounge with David Nicolau, PharmD, titled Fetroja® (cefiderocol), An Overview of In Vitro and Clinical Data on Friday, October 13, from 10:15 – 11:00 AM ET.

ANI Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance  

Retrieved on: 
Wednesday, August 9, 2023

-- Generics, Established Brands and Others reported net sales of $92.2 million, representing year-over-year growth of 44.9% --

Key Points: 
  • “The second quarter of 2023 was another strong quarter for ANI, across all areas of the business.
  • The Company is proud to report record net revenues and adjusted non-GAAP EBITDA and raise full-year 2023 guidance for the second quarter in a row.
  • Second Quarter and Recent Business Highlights:
    Revenues for our lead asset, Cortrophin Gel, totaled $24.3 million for the second quarter of 2023.
  • Sales of generic pharmaceuticals products, established brands and others grew 44.9% year-over-year in the second quarter of 2023.

North America Dominates the Global Gabapentin Market with Developed Healthcare System and High Adoption Rates - ResearchAndMarkets.com

Retrieved on: 
Monday, August 7, 2023

The global gabapentin market size is expected to reach USD 3.07 billion by 2030, expanding at a CAGR of 5.35% from 2023 to 2030.

Key Points: 
  • The global gabapentin market size is expected to reach USD 3.07 billion by 2030, expanding at a CAGR of 5.35% from 2023 to 2030.
  • The other key growth driver is the rising geriatric population which is more to epilepsy and conditions such as neuropathic pain.
  • Moreover, developed regions such as North America and Europe are further making policy changes to reduce the burden on the healthcare system by promoting the use of generics such as gabapentin.
  • North America is expected to dominate the market over the forecast period, due to a developed healthcare system that facilitates the adoption of drugs such as gabapentin.